Probiotic Lactobacillus rhamnosus EM1107 prevents hyperglycemia, alveolar bone loss, and inflammation in a rat model of diabetes and periodontitis

Abstract

Background This study evaluated the antihyperglycemic, anti–bone‐resorptive, and anti‐inflammatory efficacy of the probiotic Lactobacillus rhamnosus EM1107 in an experimental model of ligature‐induced periodontitis in diabetic rats treated with metformin (Met). Methods A total of 114 male Wistar rats was randomly divided into six groups: (1) control, (2) experimental periodontitis (EP), (3) EP + diabetes mellitus (DM), (4) EP + probiotic (Prob), (5) EP + DM + Prob, and (6) EP + DM + Prob + Met. The animals received probiotic gavage during the 30 days of the experiment. DM was induced on the 14th day of the experiment with a single injection of streptozotocin into the penile vein, followed by ligature for EP induction and Met gavage on the 19th day and euthanasia on the 30th day. Heart blood, gingival and periodontal tissue, and hemimaxillae were collected. Biomolecular analysis, immunoenzymatic assays, histomorphology, and microtomographic analysis were performed. Data were statistically analyzed (p < 0.05). Results There was a significant reduction in interleukin‐1β (IL‐1β) and tumor necrosis factor‐α (TNF‐α) in the Prob groups (p < 0.05) as well as in blood glucose levels in the Prob and Met groups (p < 0.001). In addition, histomorphological analysis revealed that the Prob groups had a reduction in inflammatory infiltrate. Tartrate‐resistant acid phosphatase (TRAP) and microtomographic analyses showed that the EP/DM/Prob/Met group had significantly lower linear and volumetric bone loss than those who had no treatment (p < 0.01). SOD and GPx immunostaining decreased in all groups receiving probiotics. Conclusion The findings suggest the immunoinflammatory efficacy of the probiotic L. rhamnosus EM1107 administered either alone or in association with Met in type 1 DM associated with periodontitis.

Mechanism of action of gut microbiota and probiotic Lactobacillus rhamnosus GG on skeletal remodeling in mice

“…Precise microbiome can be used in medicine to treat not only intestine‐related disorders but can also be used to improve the health of skin, liver, brain and other distant organ systems. There are several reports, supports the notion of using probiotics in precise medicine such as some strains of Lactobacillus used to prevent hyperglycaemia, alveolar bone loss and inflammation in murine models of inflammation, diabetes and periodontitis 121,122 and osteoporosis.…”

The combined orthodontic and restorative treatment for patients with malocclusion and dentition defects: A randomized controlled trial

“…[ 16 ] Additionally, other variables could have a significant influence. In fact tooth brushing movement [ 17 ] and probiotics have been demonstrated to have an influence on plaque and other periodontal parameters in pediatric, [ 18 ] periodontal, [ 19 ] and surgical [ 20 ] patients. These techniques and compounds should be evaluated in combination with orthodontic treatment in future clinical trials.…”

Microbiome‐based therapies for periodontitis and peri‐implantitis

“…Administration of L. rhamnosus EM1107 reduces levels of interleukin-1β (IL-1β) and TNF-α in gingival tissue fragments and alleviates bone loss in periodontitis rats, suggesting its anti-boneresorption and anti-inflammation efficacy (Silva, Cruz, et al, 2022).…”